Ohcanbohtosat - Eline Menu

Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy Dahkki Yanmeng Wang, Niels Vandewalle, Kim De Veirman, Karin Vanderkerken, Eline Menu, Elke De Bruyne

Viečča ollesdeavstta

Fueling CARs: metabolic strategies to enhance CAR T-cell therapy Dahkki Arne Van der Vreken, Karin Vanderkerken, Elke De Bruyne, Kim De Veirman, Karine Breckpot, Eline Menu

Viečča ollesdeavstta

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells Dahkki Liesbeth Bieghs, Jo Caers, Elke De Bruyne, Els Van Valckenborgh, Fiona Higginbotham, Karin Vanderkerken, Eline Menu

Viečča ollesdeavstta

Targeting Caveolin‐1 in Multiple Myeloma Cells Enhances Chemotherapy and Natural Killer Cell‐Mediated Immunotherapy Dahkki Dewen Zhan, Zhimin Du, Shang Zhang, Juanru Huang, Jian Zhang, Hui Zhang, Zhongrui Liu, Eline Menu, Jinheng Wang

Viečča ollesdeavstta

AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies Dahkki Niels Vandewalle, Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman

Viečča ollesdeavstta

S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma Dahkki Yanmeng Wang, Catharina Muylaert, Arne Wyns, Philip Vlummens, Kim De Veirman, Karin Vanderkerken, Esther Zaal, Celia Berkers, Jérome Moreaux, Elke De Bruyne, Eline Menu

Viečča ollesdeavstta

Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition Dahkki Mérédis Favreau, Koen Venken, Sylvia Faict, Ken Maes, Kim De Veirman, Elke De Bruyne, Xavier Leleu, Louis Boon, Dirk Elewaut, Karin Vanderkerken, Eline Menu

Viečča ollesdeavstta

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma Dahkki Chenggong Tu, Arne Van der Vreken, Fien Meeus, Lauren van den Broecke, Jack Brons, Kim De Veirman, Karin Vanderkerken, Elke De Bruyne, Karine Breckpot, Eline Menu

Viečča ollesdeavstta

Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma Dahkki Jo Caers, Dirk Hose, Ine Kuipers, Tomas Jan Bos, Els Van Valckenborgh, Eline Menu, Elke De Bruyne, Hartmut Goldschmidt, Ben Van Camp, Bernard Klein, Karin Vanderkerken

Viečča ollesdeavstta

Syntenin inhibition impairs stroma‐tumor communication in multiple myeloma and improves bortezomib treatment efficiency Dahkki Chenggong Tu, Raphael Leblanc, Arne Van der Vreken, Marnix Koops, Stephane Audebert, Lauriane Goullieux, Sofie Meeussen, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Guido David, Tom Cupedo, Pascale Zimmermann, Eline Menu

Viečča ollesdeavstta

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism Dahkki Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu

Viečča ollesdeavstta

The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse Dahkki Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, Robbe Heestermans, Hatice Satilmis, Emma Verheye, Elina Alaterre, Catharina Olsen, Nathan De Beule, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne

Viečča ollesdeavstta

Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy Dahkki Eline Menu, Lorenzo Franceschini, Karin Vanderkerken, Elke De Bruyne, Karine Breckpot, Kim De Veirman, Arne Van der Vreken, Fabien Thery, Chenggong Tu, Kevin Mwangi, Sofie Meulewaeter, Lien De Beck, Edith Janssens, Francis Impens, Rein Verbeke, Ine Lentacker

Viečča ollesdeavstta

Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia Dahkki Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman

Viečča ollesdeavstta

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma Dahkki Marie Törngren, Rong Fan, Eline Menu, Helena Eriksson, Karin Vanderkerken, Andrew Chantry, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Holly Evans, Nathan De Beule, Dirk Hose, Ken Maes, Karine Breckpot, Kim De Veirman

Viečča ollesdeavstta

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma Dahkki Martina Emde-Rajaratnam, Susanne Beck, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose

Viečča ollesdeavstta

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade Dahkki Torstein Baade Rø, Rui Yang, Zachary Cooper, Richard Woessner, Samah Elsaadi, Kristine Misund, Pegah Abdollahi, Esten Nymoen Vandsemb, Siv Helen Moen, Anna Kusnierczyk, Geir Slupphaug, Therese Standal, Anders Waage, Tobias S Slørdahl, Even Rustad, Anders Sundan, Carl Hay, Alwin G Schuller, Alexandra Borodovsky, Eline Menu, Magne Børset, Anne Marit Sponaas

Viečča ollesdeavstta

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape Dahkki Arne Van der Vreken, Fien Meeus, Chenggong Tu, Lauren van den Broecke, Vincenzo Raimondi, Rosanna Vescovini, Heleen Hanssens, Fenja Watté, Dorien Autaers, Marta Marco Aragon, Janne Billiau, Kim De Veirman, Karin Vanderkerken, Yannick De Vlaeminck, Lorenzo Franceschini, Holly Lee, Paola Neri, Elke De Bruyne, Paola Storti, Nicola Giuliani, Karine Breckpot, Eline Menu

Viečča ollesdeavstta

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma Dahkki Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger, Eline Menu, Elke de Bruyne, Michael Gelinsky, Marian Kampschulte, Marcus Rohnke, Sabine Wenisch, Karin Vanderkerken, Thomas Hanke, Anja Seckinger, Volker Alt

Viečča ollesdeavstta

Correction: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma Dahkki Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger, Eline Menu, Elke de Bruyne, Michael Gelinsky, Marian Kampschulte, Marcus Rohnke, Sabine Wenisch, Karin Vanderkerken, Thomas Hanke, Anja Seckinger, Volker Alt

Viečča ollesdeavstta